版本:
中国

Bayer ups sales targets for top-selling drugs after Monsanto deal

FRANKFURT, Sept 20 German drugmaker Bayer said its two best-selling drugs had a higher annual peak sales potential than previously targeted, after the agreed $66 billion takeover of Monsanto stirred criticism it might neglect its pharmaceuticals business.

Bayer now expects annual peak sales of more than 5 billion euros ($5.6 billion) for stroke prevention pill Xarelto, jointly sold with Johnson & Johnson, where it had previously seen about 3.5 billion.

For the eye medicine Eylea, jointly developed with Regeneron , it now sees peak sales potential of more than EUR 2.5 billion, up from at least 1.5 billion euros previously.

($1 = 0.8950 euros) (Reporting by Ludwig Burger; Editing by Tina Bellon)

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐